lestaurtinib has been researched along with Myeloproliferative Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Kumar, C; Lee, FY; Lorenzi, MV; Purandare, AV | 1 |
| Verstovsek, S | 1 |
| Geyer, HL; Mesa, RA; Tibes, R | 1 |
| Benson, KL; Bogenberger, JM; Mesa, RA; Tibes, R | 1 |
| Angeles, T; Carroll, M; Dobrzanski, P; Emerson, SG; Hexner, EO; Jan, M; Robinson, C; Ruggeri, B; Serdikoff, C; Swider, CR; Yang, S | 1 |
4 review(s) available for lestaurtinib and Myeloproliferative Disorders
| Article | Year |
|---|---|
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Kinase drug discovery approaches in chronic myeloproliferative disorders.
Topics: Carbazoles; Chronic Disease; Drug Discovery; Furans; Humans; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors | 2009 |
Therapeutic potential of JAK2 inhibitors.
Topics: Animals; Carbazoles; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Furans; Humans; Janus Kinase 2; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Point Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidines; Signal Transduction; Splenomegaly; Sulfonamides; Weight Gain | 2009 |
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Benzamides; Bridged-Ring Compounds; Carbazoles; Chromatin; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Furans; Gene Expression Regulation; Humans; Ikaros Transcription Factor; Intracellular Signaling Peptides and Proteins; Isocitrate Dehydrogenase; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Polycomb Repressive Complex 2; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Pyrazoles; Pyrimidines; Pyrrolidines; Receptors, Thrombopoietin; Repressor Proteins; Signal Transduction; Spliceosomes; Sulfonamides | 2012 |
2 other study(ies) available for lestaurtinib and Myeloproliferative Disorders
| Article | Year |
|---|---|
JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Topics: Animals; Benzamides; Bridged-Ring Compounds; Carbazoles; Furans; Humans; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidines; Sulfonamides | 2012 |
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Topics: Animals; Bone Marrow Cells; Carbazoles; Cell Division; Cells, Cultured; Erythroid Cells; Furans; Hematopoietic Stem Cells; Humans; Janus Kinase 2; Mice; Mice, Nude; Mutation; Myeloproliferative Disorders; Phenotype; Phosphorylation; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2008 |